Protagenic Therapeutics, Inc.\New (PTIXW) — 8-K Filings

8-K Filings (26)

• Protagenic Therapeutics Appoints New Directors and CMO — Nov 5, 2025 Risk: medium
  Protagenic Therapeutics, Inc. announced on November 3, 2025, changes in its board of directors and executive compensation. Specifically, the company elected two
• Protagenic Therapeutics Files 8-K — Oct 31, 2025 Risk: medium
  Protagenic Therapeutics, Inc. filed an 8-K on October 31, 2025, reporting an event that occurred on October 28, 2025. The filing indicates a change in the compa
• Protagenic Therapeutics Faces Delisting Concerns — Aug 22, 2025 Risk: high
  Protagenic Therapeutics, Inc. filed an 8-K on August 22, 2025, reporting a notice of delisting or failure to satisfy continued listing rules as of August 7, 202
• Protagenic Therapeutics Reports Key Corporate Events — Aug 13, 2025 Risk: medium
  Protagenic Therapeutics, Inc. filed an 8-K on August 13, 2025, reporting on several events that occurred on August 7, 2025. These include cost associated with e
• Protagenic Therapeutics Files 8-K — Jul 30, 2025 Risk: low
  Protagenic Therapeutics, Inc. filed an 8-K on July 30, 2025, reporting an event on July 18, 2025. The filing primarily concerns Regulation FD Disclosure and Fin
• Protagenic Therapeutics Announces Board and Executive Changes — Jul 24, 2025 Risk: medium
  Protagenic Therapeutics, Inc. announced on July 18, 2025, changes in its board of directors and executive compensation arrangements. The filing details the depa
• Protagenic Therapeutics Files 8-K — Jun 27, 2025 Risk: low
  On June 24, 2025, Protagenic Therapeutics, Inc. filed an 8-K report detailing material modifications to the rights of security holders and financial statements.
• Protagenic Therapeutics Files 8-K — May 21, 2025 Risk: low
  Protagenic Therapeutics, Inc. filed an 8-K on May 21, 2025, reporting an event on May 15, 2025. The filing pertains to Regulation FD Disclosure and Financial St
• Protagenic Therapeutics Files 8-K on Agreements and Equity Sales — May 20, 2025 Risk: medium
  Protagenic Therapeutics, Inc. filed an 8-K on May 20, 2025, reporting on the entry into a material definitive agreement and unregistered sales of equity securit
• Protagenic Therapeutics Reports Multiple Material Events — May 19, 2025 Risk: medium
  Protagenic Therapeutics, Inc. filed an 8-K on May 19, 2025, reporting several material events. These include entering into a material definitive agreement, comp
• Protagenic Therapeutics Files 8-K — May 5, 2025 Risk: low
  Protagenic Therapeutics, Inc. filed an 8-K on May 2, 2025, reporting amendments to its articles of incorporation or bylaws and financial statements. The company
• Protagenic Therapeutics Files 8-K — Apr 29, 2025 Risk: low
  Protagenic Therapeutics, Inc. filed an 8-K on April 29, 2025, reporting information under Regulation FD and including financial statements and exhibits. The com
• Protagenic Therapeutics Files 8-K on Shareholder Vote Matters — Apr 18, 2025 Risk: low
  Protagenic Therapeutics, Inc. filed an 8-K on April 18, 2025, reporting a submission of matters to a vote of security holders. The company, previously known as
• Protagenic Therapeutics Files 8-K on Security Holder Vote Matters — Feb 24, 2025 Risk: low
  On February 21, 2025, Protagenic Therapeutics, Inc. filed an 8-K report detailing a submission of matters to a vote of its security holders. The company, incorp
• Protagenic Therapeutics Faces Delisting Concerns — Jan 29, 2025 Risk: high
  Protagenic Therapeutics, Inc. filed an 8-K on January 29, 2025, reporting a notice of delisting or failure to satisfy a continued listing rule or standard, with
• Protagenic Therapeutics Faces Delisting Concerns — Jan 16, 2025 Risk: high
  Protagenic Therapeutics, Inc. filed an 8-K on January 16, 2025, reporting a notice of delisting or failure to satisfy a continued listing rule. The earliest eve
• Protagenic Therapeutics Enters Material Definitive Agreement — Jan 10, 2025 Risk: medium
  Protagenic Therapeutics, Inc. announced on January 9, 2025, that it entered into a material definitive agreement. The filing does not provide specific details a
• Protagenic Therapeutics Files 8-K for Other Event — Dec 3, 2024 Risk: medium
  Protagenic Therapeutics, Inc. filed an 8-K on November 29, 2024, reporting an "Other Event." The filing does not contain specific details about the event, its f
• Protagenic Therapeutics Faces Delisting Concerns — Nov 22, 2024 Risk: high
  Protagenic Therapeutics, Inc. filed an 8-K on November 22, 2024, reporting a notice of delisting or failure to satisfy a continued listing rule or standard. The
• Protagenic Therapeutics Files 8-K — Nov 5, 2024 Risk: low
  Protagenic Therapeutics, Inc. filed an 8-K on November 4, 2024, reporting on several events. The filing includes information related to financial statements and
• Protagenic Therapeutics Files 8-K: Material Agreement & Equity — Oct 30, 2024 Risk: medium
  On October 29, 2024, Protagenic Therapeutics, Inc. entered into a material definitive agreement, likely related to the issuance of unregistered equity securitie
• Protagenic Sells Subsidiary — Sep 18, 2024 Risk: medium
  Protagenic Therapeutics, Inc. announced on September 17, 2024, that it has entered into a definitive agreement to sell its wholly-owned subsidiary, Protagenic B
• Protagenic Therapeutics Faces Delisting Concerns — Jul 26, 2024 Risk: high
  Protagenic Therapeutics, Inc. filed an 8-K on July 26, 2024, reporting a notice of delisting or failure to satisfy continued listing rules as of July 24, 2024.
• Protagenic Therapeutics Faces Delisting Concerns — May 24, 2024 Risk: high
  Protagenic Therapeutics, Inc. filed an 8-K on May 24, 2024, reporting a notice of delisting or failure to satisfy a continued listing rule or standard. The comp
• Protagenic Therapeutics Files 8-K — May 22, 2024 Risk: low
  Protagenic Therapeutics, Inc. filed an 8-K on May 22, 2024, reporting a Regulation FD Disclosure and Financial Statements and Exhibits. The company, formerly kn
• Protagenic Therapeutics Files 8-K — Mar 21, 2024 Risk: low
  Protagenic Therapeutics, Inc. filed an 8-K on March 21, 2024, reporting events that occurred on March 19, 2024. The filing includes information related to Regul

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX